Biosimilar Market in Europe Share, Size, Industry Growth and Analysis Report 2024-2032

Biosimilar Market in Europe 2024-2032

According to IMARC Group's report titled "Biosimilar Market in Europe Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab), Indication (Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility), Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Country 2024-2032", the report presents a thorough review featuring the market share, growth, share, trends, and research of the industry.

How Big is the Biosimilar Industry in Europe?

The biosimilar market in Europe size reached USD 11,849.5 Million in 2023. Looking forward, IMARC Group expects the market to reach USD 53,222.9 Million by 2032, exhibiting a growth rate (CAGR) of 17.6% during 2024-2032.

For an in-depth analysis, you can refer free sample copy of the report: https://www.imarcgroup.com/europe-biosimilar-market/requestsample

Biosimilar Market in Europe Trends:

The market in Europe is primarily driven by the rising demand for cost-effective treatment options, particularly among patients with chronic diseases. In line with this, the increasing prevalence of biologic drugs nearing patent expiration is augmenting the availability of biosimilars, facilitating market growth. Moreover, the improving healthcare infrastructure across the region is enabling wider adoption of biosimilars, supported by favourable regulatory frameworks.

Furthermore, inflating healthcare expenditure in Europe is empowering patients and providers to consider biosimilars as viable alternatives. Additionally, the escalating focus on reducing overall healthcare costs is promoting biosimilar uptake, as they offer significant savings without compromising treatment efficacy, thereby propelling the market. Besides, the growing support from government bodies and health organizations for biosimilar development is acting as a significant growth-inducing factor. Also, rising awareness campaigns highlighting the safety and efficacy of biosimilars are encouraging their acceptance among healthcare professionals and patients. The increasing investments by pharmaceutical companies in biosimilar research and development are further fostering the market, paving the way for innovation and competition.

Biosimilar Market in Europe Scope and Growth Analysis:

The market scope is broadening significantly due to increasing therapeutic applications in areas such as oncology, immunology, and endocrinology, which are addressing unmet clinical needs. Additionally, the rising adoption of biosimilars in hospital settings is facilitating their integration into mainstream treatment protocols, strengthening the market's position. Moreover, the inflating availability of affordable biosimilar drugs is enabling equitable access to advanced therapies, especially in emerging economies within Europe.

Besides, the robust collaboration between regulatory authorities and pharmaceutical companies is fostering an efficient approval process, accelerating product launches. The expanding presence of local manufacturers is further diversifying the market, catering to region-specific demands and preferences. Also, the adoption of advanced manufacturing technologies is improving production efficiency, reducing costs, and improving supply chain dynamics. Apart from this, the increasing emphasis on biosimilar interchangeability is instilling confidence among prescribers, augmenting the market's acceptance. As per market analysis, the changing reimbursement policies supporting biosimilar adoption are influencing the market outlook by creating a more favourable environment for industry players and healthcare systems alike.

IMARCs report provides a deep dive into the biosimilar market in Europe analysis, outlining the current trends, underlying market demand, and growth trajectories.

By the IMARC Group, the Top Competitive Landscapes Operating in the Industry:

Novartis
Pfizer
Teva
Celltrion
Merck Sharp & Dohme
Samsung Bioepis
Eli Lilly
Accord Healthcare Ltd.
Amgen
Boehringer Ingelheim
Hexal Ag
Apotex
Stada Arzneimittel Ag
Ratiopharm
Mylan

Biosimilar Market in Europe Market Research and Segmentation:

The market report offers a comprehensive analysis of the segments, highlighting those with the largest biosimilar market in Europe share. It includes forecasts for the period 2024-2032 and historical data from 2018-2023 for the following segments.

Breakup by Molecule:

Infliximab
Insulin Glargine
Epoetin Alfa
Etanercept
Filgrastim
Somatropin
Rituximab
Follitropin Alfa
Adalimumab

Breakup by Indication:

Auto-Immune Diseases
Blood Disorder
Diabetes
Oncology
Growth Deficiency
Female Infertility

Breakup by Manufacturing Type:

In-house Manufacturing
Contract Manufacturing

Breakup by Country:

Italy
Germany
United Kingdom
France
Spain
Rest of Europe

Ask Analyst For Customization: https://www.imarcgroup.com/request?type=report&id=1023&flag=C

Key highlights of the Report:

Market Performance (2018-2023)
Market Outlook (2024-2032)
COVID-19 Impact on the Market
Porter’s Five Forces Analysis
Strategic Recommendations
Historical, Current and Future Market Trends
Market Drivers and Success Factors
SWOT Analysis
Structure of the Market
Value Chain Analysis
Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145